Literature DB >> 8090761

Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells.

T Ueba1, T Nosaka, J A Takahashi, F Shibata, R Z Florkiewicz, B Vogelstein, Y Oda, H Kikuchi, M Hatanaka.   

Abstract

Mutations of the p53 gene are found in various human cancers. The frequency of its mutation is reported to increase during tumor progression in most tumors. In human gliomas, mutations of the p53 gene are found in about one-third of the malignant forms and in few of the benign ones, indicating their possible involvement in tumor progression. On the other hand, we have recently shown that basic fibroblast growth factor (basic FGF) plays a crucial role in tumor progression as an autocrine growth factor in tissues of human gliomas. Therefore, we hypothesized that p53 might regulate the promoter activity of the basic FGF gene, which has several GC boxes and no typical TATA box. In this study, cotransfection assays using human glioblastoma and hepatocellular carcinoma cells and establishment of stable cell lines expressing mutant-type p53 were performed. The basic FGF gene promoter was demonstrated to be regulated by p53 at the transcriptional level and its basal core promoter was found to be responsive to p53. Expression of endogenous basic FGF was also demonstrated to be activated by mutant type p53. Wild-type p53 repressed gene expression of the basic FGF and its mutant activated it in vitro, implying one of the possible pathways in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090761      PMCID: PMC44736          DOI: 10.1073/pnas.91.19.9009

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  The MCK enhancer contains a p53 responsive element.

Authors:  H Weintraub; S Hauschka; S J Tapscott
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 2.  TBP, a universal eukaryotic transcription factor?

Authors:  N Hernandez
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

3.  Acidic and basic fibroblast growth factors are present in glioblastoma multiforme.

Authors:  D F Stefanik; L R Rizkalla; A Soi; S A Goldblatt; W M Rizkalla
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

4.  Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues.

Authors:  T Ueba; J A Takahashi; M Fukumoto; M Ohta; N Ito; Y Oda; H Kikuchi; M Hatanaka
Journal:  Neurosurgery       Date:  1994-02       Impact factor: 4.654

5.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.

Authors:  U Santhanam; A Ray; P B Sehgal
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

6.  Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor.

Authors:  J A Takahashi; M Fukumoto; Y Kozai; N Ito; Y Oda; H Kikuchi; M Hatanaka
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

7.  Wild-type p53 can down-modulate the activity of various promoters.

Authors:  D Ginsberg; F Mechta; M Yaniv; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

8.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.

Authors:  D H Mack; J Vartikar; J M Pipas; L A Laimins
Journal:  Nature       Date:  1993-05-20       Impact factor: 49.962

9.  Regulation of the human hsp70 promoter by p53.

Authors:  S N Agoff; J Hou; D I Linzer; B Wu
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

10.  Characterization of high-molecular-mass forms of basic fibroblast growth factor produced by hepatocellular carcinoma cells: possible involvement of basic fibroblast growth factor in hepatocarcinogenesis.

Authors:  Y Shimoyama; M Gotoh; Y Ino; M Sakamoto; K Kato; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1991-11
View more
  28 in total

1.  Defective p53 antiangiogenic signaling in glioblastoma.

Authors:  Benjamin Berger; David Capper; Dieter Lemke; Philipp-Niclas Pfenning; Michael Platten; Michael Weller; Andreas von Deimling; Wolfgang Wick; Markus Weiler
Journal:  Neuro Oncol       Date:  2010-05-26       Impact factor: 12.300

2.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Proteolysis by calpains: a possible contribution to degradation of p53.

Authors:  M Pariat; S Carillo; M Molinari; C Salvat; L Debüssche; L Bracco; J Milner; M Piechaczyk
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

4.  Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.

Authors:  Basavaraj Vastrad; Chanabasayya Vastrad; Ashok Godavarthi; Raghu Chandrashekar
Journal:  Med Oncol       Date:  2017-09-26       Impact factor: 3.064

5.  A dyad symmetry element in the fibroblast growth factor-2 gene promoter with different levels of activity in astrocytoma and hepatocelluar carcinoma cell lines.

Authors:  Tetsuya Ueba; Hisae Mori; Jun A Takahashi; Kazuhiko Nozaki; Nobuo Hashimoto
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

6.  The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis.

Authors:  Sylvia Vong; Raghu Kalluri
Journal:  Genes Cancer       Date:  2011-12

7.  Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

Authors:  J H Ludes-Meyers; M A Subler; C V Shivakumar; R M Munoz; P Jiang; J E Bigger; D R Brown; S P Deb; S Deb
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

8.  An A/G-rich motif in the rat fibroblast growth factor-2 gene confers enhancer activity on a heterologous promoter in neonatal rat cardiac myocytes.

Authors:  K A Detillieux; A F Meyers; J T Meij; P A Cattini
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

Review 9.  Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Authors:  J P Crew; T S O'Brien; A L Harris
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 10.  Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Authors:  Alessia Bottos; Alberto Bardelli
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.